BMX 001

Drug Profile

BMX 001

Alternative Names: BMX-001

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke University
  • Developer BioMimetix; Duke University; University of Colorado at Denver
  • Class Metalloporphyrins; Skin disorder therapies
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioma
  • Phase I Anal cancer; Head and neck cancer
  • Preclinical Atopic dermatitis

Most Recent Events

  • 28 Nov 2017 Phase-I clinical trials in Anal cancer in USA (SC) (NCT03386500)
  • 19 Apr 2017 Phase-I clinical trials in Head and neck cancer (Newly diagnosed, Late-stage disease) in USA (SC) (NCT02990468)
  • 08 Dec 2016 BioMimetix plans a phase I trial for Head and neck cancer (Newly diagnosed; Late-stage disease) in USA (NCT02990468)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top